Loading…
Liver-disease company: owns FibroScan liver-stiffness scanners through French unit Echosens and sells the liver-fibrosis drug Fufang Biejia Ruangan.
Liver-disease company: owns FibroScan liver-stiffness scanners through French unit Echosens and sells the liver-fibrosis drug Fufang Biejia Ruangan.
Pairs a diagnostic with a treatment in one disease area: FibroScan scanners, made by its French unit Echosens, are sold to hospitals and clinics for non-invasive liver testing, and a protected traditional Chinese medicine for liver fibrosis is sold through pharmaceutical distributors. Echosens sells in China and overseas and holds the core elastography patents.
Moat: narrow (IP / patents, installed base). Pioneer of transient elastography with a large installed base; the drug is a nationally protected Chinese patent medicine.
Headquarters: Beijing, China · Founded: 2001 · Employees: 964
Size Inner Mongolia Furui Medical Science (300049.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.85B, the 1359th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥47.89 on 6 Nov 2026.
Performance Over six months the shares fell 4.9%, against -4.2% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 11.3% over the last twelve months (peer median +10.9%); the operating margin is 25.5% (peer median 10.9%).
Valuation It trades at 53.2× forward earnings against a peer median of 26.9× (2nd most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.64B | CN¥1.59B | CN¥1.35B | CN¥1.14B | CN¥998M |
| Revenue growth | — | +18% | +18% | +15% | — |
| Gross profit | CN¥1.24B | CN¥1.09B | CN¥931M | CN¥813M | CN¥698M |
| EBITDA | n/a | CN¥505M | CN¥380M | CN¥335M | CN¥255M |
| Net income | CN¥176M | CN¥154M | CN¥113M | CN¥102M | CN¥97.9M |
| Free cash flow | CN¥247M | CN¥165M | CN¥5.12M | CN¥121M | CN¥105M |
| Capital expenditure | CN¥164M | CN¥189M | CN¥219M | CN¥189M | CN¥90.8M |
| Total debt | CN¥254M | CN¥137M | CN¥83.4M | CN¥59.3M | CN¥55.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Inner Mongolia Furui Medical Science 300049.SZ | $1.85B | -5% | +11% | 25% | 53.2× | 6.6% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.4B | +9% | +5% | 28% | 27.1× | 0.9% |
| Siemens Healthineers SHL.DE | $55.9B | +31% | -1% | 15% | 18.9× | 9.0% |
| GE HealthCare GEHC | $37.2B | +30% | +7% | 14% | 15.4× | 4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300049.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.7% | -0.5% | 3rd highest of 21 |
| 6-month return | -4.9% | -4.2% | 8th lowest of 21 |
| Distance from 52-week high | -44.9% | -28.8% | 5th lowest of 21 |
| Revenue growth (TTM) | +11.3% | +10.9% | 11th highest of 21 |
| Operating margin | 25.5% | 10.9% | 3rd highest of 21 |
| Forward P/E | 53.2× | 26.9× | 2nd most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 6.6% | 13.2% | 6th least demanding of 15 |
| Growth delivered (Del g) | +14.6% | +10.9% | 4th highest of 15 |
| Hurdle (Req g minus delivered) | -8.0 pp | -4.9 pp | 7th least demanding of 15 |
| ROIC minus cost of capital | +9.6 pp | -1.3 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.85B | -5% | +11% | 25% | 53.2× | 6.6% | +14.6% |
| LeMaitre Vascular LMAT | United States | $1.85B | -25% | +12% | 29% | 26.2× | 2.9% | +14.0% |
| Inspire Medical Systems INSP | United States | $1.85B | +45% | 0% | 2% | 45.4× | 30.9% | +51.2% |
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 74.2× | n/a | n/a |
| DENTSPLY SIRONA XRAY | United States | $1.89B | -14% | -1% | 5% | 7.3× | 10.2% | +1.9% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $1.89B | +17% | +5% | 7% | 9.4× | -12.6% | +0.4% |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 40.7× | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.92B | +49% | +9% | 11% | 49.8× | 13.8% | +11.7% |
| Veracyte VCYT | United States | $1.94B | -40% | +17% | 17% | 14.9× | 15.1% | +34.5% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |
| Mehow Innovative 301363.SZ | China | $1.95B | -14% | +10% | 21% | 38.8× | 18.9% | +12.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.96B | -4% | +7% | 14% | 8.8× | -11.8% | +2.1% |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| JEOL 6951.T | Japan | $1.98B | -3% | -18% | 11% | 14.2× | 21.3% | +10.2% |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Establishment Labs ESTA | United States | $2.00B | -7% | +38% | -7% | n/a | n/a | n/a |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 52.0× | 17.9% | +12.7% |